ReIMAGINE Prostate Cancer Risk

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT04060589

Recruitment Status : Active, not recruiting

First Posted : August 19, 2019

Last Update Posted : April 11, 2022

View this study on Beta.ClinicalTrials.gov

Sponsor:

Collaborators:

Medical Research Council

Cancer Research UK

Imperial College London

King's College London

Information provided by (Responsible Party):

University College, London

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Active, not recruiting
Estimated Primary Completion Date :	May 31, 2023
Estimated Study Completion Date :	May 31, 2023

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Marsden T, Ahmed HU, Emberton M; ReIMAGINE Study Group. An update from the ReIMAGINE Prostate Cancer Risk Study (NCT04060589): A prospective cohort study in men with a suspicion of prostate cancer who are referred onto a magnetic resonance imaging-based diagnostic pathway with donation of tissue, blood, and urine for biomarker analyses. Eur Urol. 2021 Oct;80(4):398-399. doi: 10.1016/j.eururo.2021.06.011. Epub 2021 Jul 1.

To Top